dc.contributor.author | Goker, Hakan | |
dc.contributor.author | Ozdemir, Evren | |
dc.contributor.author | Uz, Burak | |
dc.contributor.author | Buyukasik, Yahya | |
dc.contributor.author | Turgut, Mehmet | |
dc.contributor.author | Serefhanoglu, Songul | |
dc.contributor.author | Ozcebe, Osman I. | |
dc.date.accessioned | 2020-06-21T14:04:13Z | |
dc.date.available | 2020-06-21T14:04:13Z | |
dc.date.issued | 2013 | |
dc.identifier.issn | 1473-0502 | |
dc.identifier.uri | https://doi.org/10.1016/j.transci.2013.07.030 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12712/15566 | |
dc.description | Haznedaroglu, Ibrahim C./0000-0001-8028-9462; Bayram, Cem/0000-0001-8717-4668; | en_US |
dc.description | WOS: 000329012500044 | en_US |
dc.description | PubMed: 23981652 | en_US |
dc.description.abstract | Due to the high transplant related morbidity and mortality (TRM), relatively younger acute leukemia patients that have a good performance status and no comorbidity are eligible for myeloablative conditioning (MAC) followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). The outcomes of 84 consecutive adult patients with ALL (n = 38) or AML (n = 46) who underwent allo-HSCT from their HLA-identical siblings were evaluated retrospectively. The median age at transplantation was 34 (17-58 years) for the whole patient population. Of these, 24 patients received a MAC and 60 patients received a fludarabine-based reduced intensity conditioning regimen (RIC). After a median follow-up of 32 months (range, 1-119), for the entire group, the 3-year estimated overall survival (OS) was 57.5% and the disease-free survival (DFS) was 51.5%. The OS for ALL and AML patients were 53.9% vs 62.1%; and DES were 50.5% and 53.4%, respectively. The 3-year estimated OS for RIC and MAC patients were 63.2% and 41.7%; and DFS were 57.1% and 34.7%, respectively. In ALL patients, conditioning regimens (RIC vs MAC) led to similar OS and DFS; however, in AML patients both OS (70.1% vs 21.4%) and DFS (59.3% vs 42.9%) were found to be higher in RIC patients compared to MAC recipients. Overall, the TRM at day 100 was 1.7% and has increased up to 5.1% at 1st year. In multivariate analysis, the diagnosis (p = 0.03) and RIC regimen (p = 0.027) were the prognostic variables for prolonged OS in all patients; and RIC regimen (p = 0.031) was the only prognostic factor for prolonged OS in AML patients. The first complete remission (CR1) was correlated with a prolonged DFS as an independent variable for all patients (p = 0.09). Eleven of the RIC patients (18.3%) and 6 of the MAC patients (25%) developed acute graft-versus-host disease (GvHD). Seventeen of the RIC patients (33.3%) and 4 of the MAC patients (16.7%) developed chronic GvHD. In conclusion, RIC conditioning regimens may provide a longer OS and DFS, especially in patients with AML who are in first CR, not eligible for MAC conditioning. (C) 2013 Elsevier Ltd. All rights reserved. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Pergamon-Elsevier Science Ltd | en_US |
dc.relation.isversionof | 10.1016/j.transci.2013.07.030 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Reduced intensity conditioning regimen | en_US |
dc.subject | Myeloablative conditioning regimen | en_US |
dc.subject | Allogeneic hematopoietic stem cell transplantation | en_US |
dc.subject | Graft-versus-host disease | en_US |
dc.title | Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: A single center experience | en_US |
dc.type | article | en_US |
dc.contributor.department | OMÜ | en_US |
dc.identifier.volume | 49 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 590 | en_US |
dc.identifier.endpage | 599 | en_US |
dc.relation.journal | Transfusion and Apheresis Science | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |